Skip to main content

Relay Therapeutics, Inc 10-Q for FY2026 Q3

Relay Therapeutics, Inc. (RLAY)

10-Q 2026-11-04 For: 2026-09-30
View Original
Added on November 04, 2026

About this 10-Q

Relay Therapeutics, Inc filed this 10-Q on November 4, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Relay Therapeutics said cash, cash equivalents and investments of $848.6 million as of September 30, 2026 should fund operations into 2029. Nine-month net loss was $238.7 million, while zovegalisib received FDA Breakthrough Therapy designation with fulvestrant. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$81.75M
compared with a net loss of $74.15M a year earlier
Diluted EPS
-$0.37
compared with -$0.43 a year earlier